AstraZeneca to conduct COVID-19 vaccine clinical trials in Peru

Photo: ANDINA/Diffusion

11:33 | Lima, Sep. 19.

British laboratory AstraZeneca will carry out phase III clinical trials of its candidate vaccine against COVID-19 on around 3,000 volunteers in Peru this October, the Ministry of Foreign Affairs has reported.

"The National Health Institute (INS), the regulating authority in Peru, authorized the British laboratory to carry out phase III clinical trials of its candidate vaccine (...). The study will include approximately 3,000 volunteers and start in early October", said a press release.

Thus, Peru participates in a study of 30,000 volunteers focused on the United States.

"It is a demonstration of trust in the capacity of Peruvian scientists and in the experience of the country's research centers," Foreign Affairs Minister Mario Lopez highlighted.

Candidate vaccine

AstraZeneca's candidate vaccine was initially studied by the University of Oxford and is one of those with the most advanced trials, "to the point that it is expected to become one of the first to be approved for commercialization.”

AstraZeneca's clinical trials in Peru will join those already started by other laboratories.

In fact, last weekend Chinese laboratory Sinopharm began the recruitment of a first group of 3,000 volunteers at Lima-based Cayetano Heredia University, which was completed in less than 15 minutes.

In the coming days, the recruitment of another group of 3,000 will continue at San Marcos University.

(END) NDP/MVB

Published: 9/19/2020

AstraZeneca to conduct COVID-19 vaccine clinical trials in Peru

Most read